Ignite Creation Date:
2025-12-24 @ 5:05 PM
Ignite Modification Date:
2025-12-29 @ 11:27 AM
Study NCT ID:
NCT05745350
Status:
RECRUITING
Last Update Posted:
2025-02-11
First Post:
2023-02-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Sponsor:
Xiaorong Dong
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-03-07
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-05
First Submit QC Date:
None
Study First Post Date:
2023-02-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-10
Last Update Post Date:
2025-02-11
Last Update Post Date Type:
ACTUAL